BV Study

计划入组 39 人

CAP 098 (BV Study)

计划入组 150 人 · 首次发布于 2026 年 7 月 6 日

Blincyto Amgen Acrotech BioPharma PH2 Blincyto Marqibo R/R Philadelphi CD19+ ALL

首次发布于 2020 年 6 月 26 日

AAV5 vector delivered ANGPTL3 gene therapy (uniQure BV)

BV-200 series

BV-5200

Medtronic BioPharma BV

Netherlands

Uniqure, Inc.

United States

Acerta Pharma BV

Netherlands

Federal Circuit Upholds Patent Invalidation of uniQure's Hemgenix Gene Therapy in Pfizer Challenge

Citryll Secures €85 Million in Series B Funding to Advance NET-Targeting Antibody CIT-013

MeMed BV Test Reduces Antibiotic Overuse in Lower Respiratory Infections